This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Cynosure Acquires Worldwide Exclusive Rights To Distribute PinPointe™ FootLaser™ For Treatment Of Onychomycosis

Stocks in this article: CYNO

WESTFORD, Mass., Oct. 5, 2011 /PRNewswire/ -- Cynosure, Inc. (NASDAQ: CYNO), a leader in laser- and light-based treatments for minimally invasive and non-invasive aesthetic applications, today announced that it has acquired from NuvoLase, Inc. worldwide exclusive rights to distribute the PinPointe™ FootLaser™.  The PinPointe FootLaser is the world's first FDA cleared light-based device for the treatment of Onychomycosis (toenail fungus), a condition that affects approximately 36 million people in the United States and an estimated 10 percent of the population worldwide.

The PinPointe FootLaser received U.S. Food and Drug Administration clearance in October 2010 for the treatment of Onychomycosis.  The system also is cleared for marketing in Australia, Canada and the European Union.

"The treatment of Onychomycosis represents an emerging opportunity for light-based technology," said Cynosure President and Chief Executive Officer Michael Davin. "We are acquiring the worldwide exclusive rights to a system that we believe is considered the leading solution for treating this indication.  With almost 100,000 PinPointe FootLaser treatments performed worldwide to date, our distribution agreement with NuvoLase immediately gives us a leadership position in the market."

The distribution agreement gives Cynosure rights to distribute both current and future NuvoLase products for the treatment of Onychomycosis.  In North America, Cynosure plans to sell the PinPointe FootLaser through a new dedicated podiatry direct sales team supported by the Company's existing direct sales force.  The American Podiatric Medical Association estimates that there are approximately 15,000 podiatrists currently practicing in the United States.  In Europe, the system will initially be marketed through Cynosure's direct subsidiaries.  Cynosure expects to launch the product in additional markets in the Asia Pacific region and through select international distributors in the future.

"We believe Cynosure's expansive distribution network will help drive the adoption of the PinPointe FootLaser system on a global basis," said NuvoLase President and Chief Executive Officer Steven P. Duddy.  "The expertise Cynosure has demonstrated in developing and marketing laser- and light-based treatments for minimally invasive and non-invasive aesthetic applications will be crucial in gaining market share for this fast-growing indication."

Onychomycosis is a condition marked by the growth of fungus under the nail.  Fungi feed on keratin, the protein that makes up the hard surface of the toenails.  The infected nail often turns darker in color, and debris may accumulate under the nail.  As the infection continues, the nail either may crumble gradually and fall off or thicken.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,810.06 +91.06 0.51%
S&P 500 2,063.50 +10.75 0.52%
NASDAQ 4,712.97 +11.1030 0.24%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs